S100A2, human, recombinant, full length
- Known as:
- S100A2, H. sapiens, Rec., length
- Catalog number:
- G02S1A02
- Product Quantity:
- 5 mg
- Category:
- -
- Supplier:
- Giotto Biotech
- Gene target:
- S100A2 human recombinant full length
Related genes to: S100A2, human, recombinant, full length
- Gene:
- S100A2 NIH gene
- Name:
- S100 calcium binding protein A2
- Previous symbol:
- S100L
- Synonyms:
- CAN19
- Chromosome:
- 1q21.3
- Locus Type:
- gene with protein product
- Date approved:
- 1993-10-04
- Date modifiied:
- 2016-10-05
Related products to: S100A2, human, recombinant, full length
Related articles to: S100A2, human, recombinant, full length
- The tumor downstaging and pathological complete response of bladder cancer were found to be improved with the application of neoadjuvant chemotherapy combined with immunotherapy. However, about 34.2% of patients with muscle-invasive bladder cancer were insensitive or unresponsive to neoadjuvant chemoimmunotherapy. Despite the diversity of biomarkers for therapeutic effect of neoadjuvant immunotherapy or chemotherapy, biomarkers to accurately evaluate the therapeutic effect and toxicity of neoadjuvant chemoimmunotherapy in bladder cancer are currently lacking. To identify potential genomic biomarkers for the responsiveness of neoadjuvant chemoimmunotherapy, we analyzed the genomic dynamic changes of patients with muscle-invasive bladder cancer. - Source: PubMed
Publication date: 2026/05/26
Chen ChunxiaoLiu XinchengXu AbaiJiang NingWang PengLiu YazhenCheng JianzhouWang WeiLiu ChunxiaoXu Peng - Epidermal growth factor (EGF) is a therapeutically important member of a family of the growth factors that activate EGF receptors, triggering several signaling pathways vital for development, homeostasis and regeneration of many organs. Previous studies have shown the ability of S100A4, a small calcium-binding protein of the S100 family, to directly affect functional activity of EGF receptors and its ligands, including EGF. However, selectivity and functional significance of EGF-S100 interactions remain unexplored. To address this, we examined specificity of EGF for twenty-one S100 proteins using surface plasmon resonance spectroscopy. The impact of the revealed interactions on EGF-induced cellular effects was assessed using cell proliferation and metabolic activity assays. S100A2/A4/A6/A11/A12/A13/A16/P and S100A8-S100A9 heterodimer bind EGF strictly in the presence of calcium with lowest estimates of the equilibrium dissociation constant ranging from 13 nM to 1.0 μM. Structural modelling indicates involvement of α-helix IV and "hinge" region of the EGF-specific S100 proteins in the EGF binding, which was confirmed for S100P by mutagenesis. The complexation of EGF with S100A2/A6/A12/A16/P exerts distinct S100-dependent effects on viability and metabolic activity of lung adenocarcinoma A549 cells. Bioinformatics analysis showed that dysregulation of EGF and the EGF-specific S100 proteins is associated with many oncological diseases, Alzheimer's and Parkinson's diseases, psoriasis, etc. Overall, specific S100 proteins have been shown to directly modulate various aspects of EGF functioning, which may be important for ensuring efficacy of the EGFR-targeted cancer therapies, as well as for use of EGF in regenerative medicine. - Source: PubMed
Publication date: 2026/05/20
Rastrygina Victoria AVologzhannikova Alisa AChaplygina Alina VBobrova Lolita AZemskova Marina YDeryusheva Evgenia ISokolov Andrey SPermyakova Maria ELitus Ekaterina AUversky Vladimir NPermyakov Eugene APermyakov Sergei E - The increase in incidence of early-onset pancreatic cancer (EOPC) is of concern and poorly understood. The aim of this study was to investigate the clinical outcomes of surgically resected patients with EOPC and the potential molecular heterogeneity between EOPC and late age-onset disease. - Source: PubMed
Dreyer Stephan BBryce AdamFroeling FiekeJackson ShannonSantana LeonorDickson Euan JCoats MariaMcKay ColinHolroyd DavidBiankin Andrew VJamieson Nigel BChang David K - : Primary open-angle glaucoma (POAG) is a leading cause of irreversible blindness worldwide, characterized by progressive optic nerve degeneration and marked molecular heterogeneity. Increasing evidence indicates that metabolic dysregulation and immune remodeling contribute to POAG pathogenesis; however, the underlying regulatory networks and reliable diagnostic biomarkers remain incompletely defined. : Bulk transcriptomic and single-cell RNA sequencing (scRNA-seq) datasets of trabecular meshwork tissues were retrieved from Gene Expression Omnibus (GEO). Differential expression analysis and weighted gene co-expression network analysis (WGCNA) were performed to identify disease-associated modules. A machine learning framework was applied to construct classification models. Estimated immune-cell fractions were assessed using CIBERSORT, followed by pathway and transcription factor analyses. Single-cell analysis was conducted to examine the cell type-specific expression patterns. : A total of 195 differentially expressed genes were identified between POAG and control samples. WGCNA revealed a lactylation-related module strongly correlated with disease status. Machine learning identified and as candidate diagnostic biomarkers with consistent classification performance across datasets. Immune infiltration analysis suggested alterations in the immune microenvironment in POAG. Single-cell data showed that the model genes exhibited sparse but non-uniform expression across cell populations. : This integrative analysis prioritizes and as candidate diagnostic biomarkers for POAG and indicates potential associations with immune-metabolic regulatory mechanisms. - Source: PubMed
Publication date: 2026/03/31
Xu YuFu XinGong YajunZeng FangyuanTang MinHu SixianHuang GuangyiTu TianxianZhou Xiaolai - [This retracts the article DOI: 10.3727/096504020X16100888208039.]. - Source: PubMed
Publication date: 2026/04/22